PFIZER INC. What is the difference in incidence of fracture in women who ever or never used DMPA for contraception?
|
|
- Maria McCoy
- 5 years ago
- Views:
Transcription
1 PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Depo- Medroxyprogesterone Acetate (DMPA) PROTOCOL NO.: Not applicable. TITLE: The Incidence of Bone Fractures in Depo-Medroxyprogesterone Acetate (DMPA) Users and Non-users in Women in the General Practice Research Database (GPRD) Study Center(s): Not applicable. This web synopsis is based on the report The Incidence of Bone Fractures in Depo-Medroxyprogesterone Acetate (DMPA) Users and Non-users in Women in the General Practice Research Database (GPRD) dated 14 Dec 2009 Study Initiation Date and Primary Completion or Completion Dates: Study start, 01 January End of the study period, 31 December Phase of Development: Not applicable Study Objective(s): The objective of this study was to increase understanding of the possible effects of depo-medroxyprogesterone acetate (DMPA) on bone health in women. Of particular interest were the following questions: METHODS What is the difference in incidence of fracture in women who ever or never used DMPA for contraception? How does incidence of fracture vary by cumulative DMPA exposure? Is there a delayed effect of DMPA on fracture rates at two or more years after the end of exposure? Study Design: The study followed a cohort of women who were in the General Practice Research Database (GPRD). Their fracture experience was assessed until the earliest of 31 December 2005, the date of fracture, death, or departure from the general practice. Using Page 1
2 prescription records, current, recent, and past periods of exposure following an injection of DMPA were defined for each woman. Users of DMPA were also classified by cumulative exposure as low (1 to 7 injections) or high ( 8 injections). Number of Subjects (Planned and Analyzed): The analyzed study cohort comprised 312,395 women and 1,722,355 person-years of follow-up. The analyzed sub-cohort (women with fracture data available for at least 6 months prior to the Index date) comprised 166,367 women. This subcohort was used for comparisons of fracture rates before and after DMPA treatment was started and for assessment of potential confounders for which information was available in the GPRD. Diagnosis and Main Criteria for Inclusion: Female subjects who met the following criteria were extracted from the GPRD: Known year of birth; Woman classified as an acceptable patient by GPRD standard criteria relating to practice registration details and other measures of data quality; and Having at least one contraceptive prescription record dated between 1 January 1987 and 31 December 2005 and occurring before she reached 50 years of age. The contraceptive record also must have been dated after the practice up-to-standard date, when the data recorded by the practice met standard GPRD criteria for quality and completeness. The contraceptive prescription also was required to be after the patient s registration in the practice but before the practice s last data collection date and the patient s transferred-out or death date (if applicable). The patient registration date is the date when the woman was first recorded by the National Health Service (NHS) as a patient of a particular general practitioner, GP. The following contraceptives were acceptable: Depo-Provera (injection 150 mg/ml) or for medroxyprogesterone acetate contraceptive injection (150 mg/ml), Nonhormonal prescription contraceptives [e.g., intrauterine device (IUD), cervical cap, or diaphragm], or Hormonal prescription contraceptives that are not DMPA (e.g., other estrogen or progesterone contraceptives or combination estrogen and progesterone contraceptives). This group includes IUDs that release estrogen or progesterone. The study cohort was divided into women who did or did not have a minimum of 6 months of history before the index contraceptive date in the same GPRD practice in which the index contraceptive had been prescribed. Study Treatment: Not applicable. Efficacy Evaluations: No efficacy evaluations were performed for this study. Page 2
3 Safety Evaluations: Rules were created to define the extent of each woman s longitudinal GPRD experience that would be used in the study. These rules applied to all the women in the large cohort and subcohort, regardless of the type of contraceptives used or amount of baseline history. The index date for observation was the date of a woman s first prescription record with a contraceptive code that occurred on or after the latest of the following events: The study start date (01 January 1987), Her registration date, The up-to-standard date for the practice in which she was registered. The termination date was the first of the following dates: The practice s last date of contributing data to GPRD; The end of the study period (31 December 2005); The woman s first fracture date after entering the study; or The date when the woman terminated from the practice due to relocation, transfer to another practice, or death. Statistical Methods: Incidence of fracture was reported by 3 types of exposure: Ever use of DMPA (any exposure, yes or no): Cumulative DMPA exposure (low vs high); and Time since exposure (current, recent, or past). For cumulative DMPA exposure, low was defined as the equivalent of 1 to 7 injections and high as the equivalent of 8 injections. For time since exposure, the definitions were: Current: Current time was defined as equivalent to active DMPA exposure time, which occurred during the DMPA episodes described above (ie, the active contraceptive time). Current exposure continued as long as DMPA prescriptions continued to occur in the data (subject to the rules for adjusting for overlaps and duplicates). Recent: This was time up to 640 days after each active DMPA episode, and before a subsequent DMPA episode or the end of follow-up. Recent days were defined as ending at 730 days after the date of the last injection (inclusive). Recent time could have been interrupted if a woman received a subsequent DMPA injection or reached the end of follow-up. Past: Past time was defined as occurring after periods of recent exposure (ie, more than 730 days after the date of the last injection) and before any subsequent DMPA episode or the end of follow-up. Presumably, the effect of DMPA on bone mineral density (BMD) Page 3
4 was virtually absent during past exposure time. Time in the past category accumulated until the start of a subsequent DMPA episode or the end of follow-up. For incidence rates, observation was terminated at the first bone fracture that occurred after a woman entered the study cohort. Fractures were classified according to the DMPA exposure of the woman on the date of the fracture. If fractures at more than one bone site occurred on the same day, only one fracture event was counted for the incidence rates. Fracture events were identified using the Read and Oxford Medical Information System (OXMIS) dictionary terms used by GPs to record fracture occurrence. Definitions of fractures were the same as those developed in the earlier feasibility study. The following individual types of fractures and categories of fractures were analyzed: Ankle Arm Clavicle Finger/toe Foot Hand Hip Leg Multiple/extensive Pelvis Ribs/sternum Shoulder Skull/face Vertebra Wrist Unspecified (no fracture site was provided in the GPRD) Unspecified osteoporotic (no fracture site; coded osteoporotic ) Long bones of the arm; Page 4
5 All fractures (any reported fracture) All fractures except fractures of the hip, fractures of the long bones of the arm and fractures of the vertebrae. All fractures except finger/toe, skull/face and unspecified Axial skeleton fractures (vertebra + pelvis) Appendicular skeleton fractures (arm + leg + wrist + ankle + hand + foot + rib/sternum + clavicle + shoulder + hip) The primary outcome was fracture at any bone site. For all analyses of exposure, the reference category was nonexposure to DMPA (non-users). RESULTS Subject Disposition and Demography: Subject disposition is not applicable since this was a retrospective database study. Subject ages at study index date are summarized for DMPA users and non-users in Figure 1. Figure 1. Age at Study Index Date in Users and Nonusers of DMPA Abbreviation: DMPA = Depo-Medroxyprogesterone Acetate Note: Users had one or more DMPA injections at any time during the study period (with or without, before or after any other contraceptives). Nonusers did not have any DMPA prescriptions during the study period. Page 5
6 Subject contraceptive use is summarized in Table 1. Table 1. Number of Women by Contraceptive Combination Used Contraception During Study Period Number of Women Percent of Cohort Nonhormonal only 15, Other hormonal only 196, Nonhormonal and other hormonal 21, Total with no DMPA exposure 233, DMPA only 23, DMPA and other hormonal 51, DMPA and nonhormonal DMPA, nonhormonal and other hormonal 3, Total with any DMPA exposure 79, Total women in cohort 312, Abbreviation: DMPA = Depo-Medroxyprogesterone Acetate Efficacy Results: No efficacy evaluations (assessment of contraceptive efficacy) were performed in this study. The primary objective of the study was patient safety as reflected by bone fracture risk. Safety Results: Table 2 summarizes the duration of study observation for the cohort. The average follow-up from index date was 5.9 years for users and 5.4 years for nonusers of DMPA. Table 2. Duration of Observation in Years Number and Percentage of Person-Years by Duration of Follow-Up Number of Women % Total Person- Years <1 45, , to <2 41, , to<3 33, , to <5 54, , to <10 82, , to <15 42, , , , Total 312, ,722, Average Person- Years per Woman Table 3 shows the potential confounders which were assessed using data available in GPRD. Each of these confounders was associated with a higher risk for fracture in this population, and was more prevalent in the DMPA user cohort; estrogen HRT has been shown to decrease fracture risk in postmenopausal women and was more prevalent in the non-user cohort. Page 6
7 Table 3. Odds Ratio for High Risk Patients to be Present in the DMPA User Cohort vs. the Non-User Cohort Risk Factor DMPA (N=41,876) Control (N=124,491) With W/O With W/O Odds Ratio 95% CI Alcohol abuse/dependence Drug abuse Inflammatory bowel disease Epilepsy Asthma Oral corticosteroids Fall Estrogen HRT Smoking (current) Pregnancy < age Abbreviations: DMPA = Depo-Medroxyprogesterone Acetate; N = number; CI = confidence interval; HRT = hormone replacement therapy; W/O = without. Table 4 shows Incidence Rate Ratios (IIR) for DMPA use in the subcohort with available pre-treatment data that would allow assessment of confounders, standardized for age and other selected factors. These data show that after standardizing for age and each potential confounder, the IRRs for any DMPA were close to the value of 1.40 that resulted from standardizing by age alone. While these risk factors were associated with increased fracture rate and were more prevalent in the DMPA users cohort, the absolute numbers of women with each risk factor (or any risk factor) were relatively small compared to the overall number of women in the study and, as shown in Table 4, did not materially affect the study results. It was therefore concluded that there was little evidence of confounding from the baseline variables for which data were available in GPRD. Unassessed confounders, for which information was not available in GPRD, may also have been present and could have affected the study results. Page 7
8 Table 4. Incidence Rate Ratios for DMPA Use, Standardized for Age and Other Selected Factors (Subcohort) Any DMPA a Potential Confounding Factors IRR 95% CI Crude IRR Standardized for age only Age (5-year groups) Standardized for age and each baseline factor b Oral corticosteroids Pregnancy < age Smoking, current Alcohol abuse Asthma Drug abuse Epilepsy Estrogen HRT Fall Past fracture, any site Inflammatory bowel disease Abbreviations: DMPA = depo-medroxyprogesterone acetate; HRT = hormone replacement therapy; IRR = incidence rate ratio; CI = Confidence Interval. a. Ever used DMPA in the study period, compared with never used DMPA. b. IRRs are standardized for age in 5-year groups and for each factor (one at a time). There was a total of 11,822 incident fractures in the study population, for an overall incidence rate of 6.9 per 1,000 person-years. After the start of treatment, the crude incidence of any fracture with any use of DMPA was 9.0 per 1,000 person-years, which was higher than that in nonusers (6.4 per 1,000 person-years). The crude incident rate ratio (IRR) for any fracture with any use of DMPA was 1.41 (95% Confidence Interval or CI: ). Table 5 presents the relative risks for fracture that were determined for the subcohort by comparing DMPA users and non-users, based on these subjects having data available before and after DMPA use was started. The results show that DMPA users had a higher fracture risk than non-users before DMPA treatment was started. The higher risk for fracture in the DMPA cohort was similarly present after DMPA use started. Within the DMPA cohort, comparing the period after DMPA treatment started to the period before DMPA treatment started, the risk ratio was 1.08 (95% CI: 0.92, 1.26) indicating that there was no significant increase in fracture risk associated with starting DMPA treatment. The non-user cohort also showed no change in fracture rate associated with starting contraception (other than DMPA). Page 8
9 Table 5. Incidence of Fractures Before and After DMPA Treatment (Pre- and Post- Index Date) in the Full Study Cohort and/or in the Sub-Cohort of Patients Having 6 Months of Pre-Index Date Data) DMPA vs Non- User: PRIOR to Initiation of DMPA or Other Index Contraceptive (subcohort)* DMPA vs Non- User: AFTER INITIATION of DMPA or Other Index Contraceptive (subcohort)* DMPA vs Non- User: AFTER INITIATION of DMPA or Other Index Contraceptive (full cohort) DMPA Users: PRIOR to vs AFTER INITIATION of DMPA Treatment (subcohort)* Non-Users: PRIOR to vs AFTER INITIATION of Index Contraceptive Method (not DMPA) N DMPA User Number With Any Fx/ Fracture 1000PY Never User (Control) Number With Any Fx/ N Fracture 1000PY 41, , , , , , Prior to Initiation After Initiation 41, , , , IRR (95% CI) p-value 1.28 ( ) ( ) < ( ) <0.001 RR (95% CI) p-value 1.08 ( ) ( ) (subcohort)* Abbreviations: DMPA = depo-medroxyprogesterone acetate; Fx = fracture; PY = person years; HRT = hormone replacement therapy; IRR = incidence rate ratio; N = number; RR = relative risk; CI = Confidence Interval. * The 'subcohort' is the 53% of the study population who had fracture data available for the 6-month period immediately prior to the Index Date (baseline) and, therefore, could be included in comparisons of fracture r 'before' vs 'after' the first recorded contraceptive prescription (Index Date). All patients (full cohort) had dat available after the Index Date and could be included in the post-index Date comparison of DMPA Users vs N Users. Page 9
10 Figure 2 shows the fracture rate in the DMPA cohort as a function of time after starting DMPA. The fracture rate for the non-user group is represented as a flat line since these subjects did not start DMPA. The fracture rate in the DMPA cohort was elevated from time=0, with no induction period evident. If the greater fracture rate in the DMPA cohort was due to the BMD decline that occurs with DMPA use, and recognizing that the BMD decline requires at least 2 years to become fully present, then an induction period would be expected before the fracture rates in the two cohorts (DMPA users and non-users) diverged. Figure 2. Crude incidence of fracture during current-recent exposure to DMPA from time of first DMPA injection (all fractures) Abbreviations: DMPA = depo-medroxyprogesterone acetate; pyrs = person years Table 6 shows the fracture risk ratios for various types of fractures. If the greater rate of fracture in the DMPA cohort was due to low BMD, then those fracture sites that are known Page 10
11 to be most sensitive to low BMD and not the result of trauma (e.g., axial skeletal fractures) would be expected to show the greatest difference between the cohorts in terms of fracture risk. In contrast, fractures of the appendicular skeleton are more likely to involve trauma, to variable degrees. Fractures of the face, skull, fingers and toes are generally recognized as not being osteoporotic fractures and are usually due to trauma. Table 6. Incident Rate Ratios (DMPA Users vs. Non-Users) in the Full Study Population During Follow-Up by Fracture Type DMPA No DMPA Fx/ Fx/ Fracture Groups N N 1000PY 1000PY IRR 95% CI All fractures All fractures (except finger/toe, skull/face, unspecified) Axial skeleton Appendicular skeleton Osteoporosis-associated fractures Vertebra Hip Wrist Pelvis Unspecified osteoporotic ND Other fractures by site Ankle Arm Clavicle Finger/toe Foot Hand Leg Multiple/extensive Rib/sternum Shoulder Skull/face Unspecified site Abbreviations: DMPA = depo-medroxyprogesterone acetate; Fx = fracture; PY = person years; HRT = hormone replacement therapy; IRR = incidence rate ratio; CI = Confidence Interval; N = number; ND = not determined. Table 7 shows the effect of duration of DMPA exposure on fracture risk, where high exposure was defined as 8 or more DMPA injections and low exposure was defined as fewer than 8 cumulative DMPA injections. Overall, low exposure to DMPA was associated with a higher risk for fracture, compared to non-users, than high exposure. The Page 11
12 study results do not provide a reason why an inverse dose response relationship was observed. Table 7. Effect of DMPA Exposure on Risk Rate Ratios After Initiation of Treatment Cohort (DMPA exposure level) DMPA (HIGH) DMPA (LOW) Non-Users Observation (PY x 1000) Fracture Groups IRR 95% CI IRR 95% CI Fx/1000PY All Fractures All Fractures (except finger/toe, skull/face, unspecified) Axial Skeleton Appendicular Skeleton Abbreviations: DMPA = depo-medroxyprogesterone acetate; Fx = fracture; PY = person years; IRR = incidence rate ratio; CI = Confidence Interval. Table 8 shows crude fracture incidence as a function of both DMPA exposure (low, high) and time since last DMPA injection ( current use of DMPA at the time of fracture; recent use, fracture occurred within the 2 years following the last DMPA injection; and past use, where the fracture occurred more than 2 years after the last DMPA injection). Compared with the incidence of 6.4 per 1,000 person-years in the unexposed women, crude fracture rates were higher in all 3 categories of exposure time since last injection, with an overall trend toward higher rates in the current usage category compared to the past usage category, but the confidence intervals for current, recent and past usage categories all overlapped and were not different. Rates were generally similar for low (1-7 injections) and high (8 or more injections) cumulative exposure in all 3 exposure-time categories, except for current time, where the fracture rate in the low cumulative exposure category (12.1) was greater than the rate in the high cumulative exposure category (6.9). Page 12
13 Table 8. Crude Incidence of Any Fracture per 1,000 Person-Years by Time from Last DMPA Injection and Cumulative Number of Injections Exposure Fractures P-Y Rate per 1,000 Crude IRR 95% CI Total 11,822 1,722, None a 8,887 1,395, Total past a 1, , Low b , High b , Total recent a , Low b , High b , Total current a , Low b , High b , Abbreviations: CI = confidence interval; DMPA = depo-medroxyprogesterone acetate; IRR = incidence rate ratio; P-Y = person-years. a. The reference level of nonexposure is composed of person-years of women who did not use DMPA and of person-years of DMPA users before their first DMPA prescription. Current exposure time is during episodes of active DMPA contraception, based on the interleaving of active 90-day exposures generated by each injection. Recent exposure time is up to 640 days after the last actively exposed day, and represents time after current exposure but less than 2 years since the last injection (not including the 90 days of current exposure time associated with the last injection). Past exposure begins after the last recently exposed day, and represents time 2 years or more after the last injection. b. Cumulative exposure was low if the woman had accumulated a history of 1 to 7 DMPA injections, and high if she had received 8 or more. Table 9 shows the rates standardized by age, using weights from the age distribution of the entire cohort person-time. The age-standardized rates, like the crude rates, were higher than the unexposed rate, and suggested a trend toward increased fracture rate from past to recent to current exposure time. With age standardization, fracture rate was markedly higher in the low exposure category among current users, compared to current users with high DMPA exposure, but this was not seen for either recent or past users. Page 13
14 Table 9. Age-Standardized Incidence of Fracture per 1,000 Person-Years by Time from Last DMPA Injection and Cumulative Number of Injections Exposure Standardized Rate per 1,000 P-Y Standardized IRR 95% CI None a Total past a Low b High b Total recent a Low b High b Total current a Low b High b Abbreviations: CI = confidence interval; DMPA = depo-medroxyprogesterone acetate; IRR = incidence rate ratio; P-Y = person years. a. The reference level of nonexposure is composed of person-years of women who did not use DMPA and of person-years of DMPA users before their first DMPA prescription. Current exposure time is during episodes of active DMPA contraception, based on the interleaving of active 90-day exposures generated by each injection. Recent exposure time is up to 640 days after the last actively exposed day, and represents time after current exposure but less than 2 years since the last injection (not including the 90 days of current exposure time associated with the last injection). Past exposure begins after the last recently exposed day, and represents time 2 years or more after the last injection. b. Cumulative exposure was low if the woman had accumulated a history of 1 to 7 DMPA injections, and high if she had received 8 or more. CONCLUSION(S): This study demonstrated that the DMPA users did not experience an increase in fracture risk after starting DMPA treatment, compared to their pre-treatment level of risk. This finding is relevant to the 5 to 6 year period after first DMPA use, which was the average observation time in this study. The study also confirmed that DMPA users differ significantly from nonusers at baseline with respect to the rate at which fractures occur, which was the primary endpoint in the study. Overall, the DMPA cohort s excess of appendicular fractures, typically related to trauma, in the face of no excess of axial fractures more likely to be related to low BMD in the absence of trauma, suggests that the mechanism for the observed difference in fracture rates at baseline could possibly be related to exposure to trauma, but information on exposure to trauma was not available in the study database; the observed differences in fracture rates do not appear to be related to use of DMPA, and hence to the BMD decline that is know to occur with DMPA use. Page 14
Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAsmall number of studies have examined
Appendix B: Evidence on Hormone Replacement Therapy and Fractures B Asmall number of studies have examined directly the relationship between use of hormonal replacement therapy and risk of hip fracture
More informationCatch the HEDIS Buzz!
Catch the HEDIS Buzz! Focus Area: Osteoporosis Management in Women Who Had a Fracture Date: October 2014 HEDIS Performance Score In 2013, Humana At Home associates did a great job of promoting Osteoporosis
More informationThe Skeletal System in Action!! The Skeletal System in Action!
Skeletal System The Skeletal System in Action!! The Skeletal System in Action! 5 Functions of the Skeletal System 1. Movement: Skeletal system provides points of attachment for muscles. Your legs and arms
More informationBone Mineral Density Studies in Adult Populations
Bone Mineral Density Studies in Adult Populations Last Review Date: July 14, 2017 Number: MG.MM.RA10aC6 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More information2. Studies of Cancer in Humans
346 IARC MONOGRAPHS VOLUME 72 2. Studies of Cancer in Humans 2.1 Breast cancer 2.1.1 Results of published studies Eight studies have been published on the relationship between the incidence of breast cancer
More informationContraception for Adolescents: What s New?
Contraception for Adolescents: What s New? US Medical Eligibility Criteria for Contraceptive Use Kathryn M. Curtis, PhD Division of Reproductive Health, CDC Expanding Our Experience and Expertise: Implementing
More informationLab-1. Miss. Lina Al-Onazy & samar Al-Wgeet =)
Lab-1 Introduction The human skeleton is composed of 300 bones at birth and by the time adulthood is reached, some bones have fused together to give a total of 206 bones in the body. The human skeleton
More informationLong Acting Reversible Methods of Contraception (LARC) in Scotland
Publication Report Long Acting Reversible Methods of Contraception (LARC) in Scotland Year ending March 2015 Publication date 3 November 2015 A National Statistics Publication for Scotland Contents Introduction...
More informationCarolyn J. Crandall, MD, MS On behalf of the WHI Bone SIG
Carolyn J. Crandall, MD, MS On behalf of the WHI Bone SIG Background One half of all postmenopausal women will have an osteoporosis related fracture during their lifetimes. Background Low body weight is
More informationUse of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
open access Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the and databases Yana Vinogradova, Carol Coupland, Julia Hippisley-Cox Division of
More informationPart I : Study of Osteoporotic Fractures (SOF) Fractures and Falls History: History of Fractures Questionnaire
PhenX Measure: Fracture History (#170900) PhenX Protocol: Fracture History (#170901) Date of Interview/Examination (MM/DD/YYYY): Part I : Study of Osteoporotic Fractures (SOF) Fractures and Falls History:
More informationRESEARCH. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database Julia Hippisley-Cox, professor of clinical epidemiology and general practice,
More informationBone (Mineral) Density Studies
Bone (Mineral) Density Studies Policy Number: Original Effective Date: MM.05.002 03/23/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Radiology Place(s) of Service:
More informationWCHQ Ambulatory Measure Specification Screening For Osteoporosis Measurement Period 07/01/16-06/30/17 Submission Period: 09/05/17-10/20/17
MEASURE DESCRIPTION The percentage of women age 65 through 85 who had a minimum of one bone densitometry test at age 60 or above or have a diagnosis of osteoporosis or osteopenia. Disclaimer: Measures
More informationChapter 6 & 7 The Skeleton
Chapter 6 & 7 The Skeleton Try this Make clockwise circles with your RIGHT foot, while doing this, draw the number 6 in the air with you RIGHT hand what happens to your foot???? Bony Background Adult body
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Warfarin and the risk of major bleeding events in patients with atrial fibrillation: a population-based study Laurent Azoulay PhD 1,2, Sophie Dell Aniello MSc 1, Teresa
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationMedroxyprogesterone 10 mg and menopause
Medroxyprogesterone 10 mg and menopause Search Millions of women worldwide, many in their teenage years, have been using the longacting, injectable depot medroxyprogesterone. L acétate de médroxyprogestérone
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationCHAPTER 8 LECTURE OUTLINE
CHAPTER 8 LECTURE OUTLINE I. INTRODUCTION A. The appendicular skeleton includes the bones of the upper and lower extremities and the shoulder and hip girdles. B. The appendicular skeleton functions primarily
More informationWhat size needle for depo provera
What size needle for depo provera The Borg System is 100 % What size needle for depo provera Jan 14, 2015. Nurse may administer Depo Provera in AIT, Same Day Clinic or by Nurse appointments. Equipment:
More informationPhase II Health Sciences as Applied to Coaching.
Phase II Health Sciences as Applied to Coaching www.topform.us Overview What is going to be covered today is.. Skeletal System Muscular System Most common injuries to know about in your sport Part One:
More informationSkeletal System. Skeleton. Support. Function of Bones. Movement. Protection 10/15/12
Skeleton Skeletal System 1 Axial Skeleton-Bones that form the longitudinal axis of the body (skull and spinal column). Appendicular Skeleton-Bones of the limbs and girdles. Also include joints, ligaments
More informationBone loss in Postmenopausal former Unidepo users
Institute of Gerontology Bone loss in Postmenopausal former Unidepo users Fatemeh Mohammadi Prof.Tengku Aizan Hamid Prof.Mohd Nazri Yazid Dr. Zanariah Othman Prof. Rozi Mahmud Introduction One of the most
More informationCopyright 2004 Lippincott Williams & Wilkins. 2. Bone Structure. Copyright 2004 Lippincott Williams & Wilkins
Chapter 7 The Skeleton: Bones and Joints The Skeleton Skeletal system is made up of bones and joints and supporting connective tissue. 1. Bone Functions 1. To store calcium salts 2. To protect delicate
More informationContraception and cancerepidemiological
Contraception and cancerepidemiological evidence Hormonal contraception Combined Progestogen-only Philip C Hannaford University of Aberdeen Breast cancer and combined oral Re-analysis of individual data
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2013 Publication date 24 September 2013 A National Statistics Publication for Scotland
More informationStrategies for data analysis: case-control studies
Strategies for data analysis: case-control studies Gilda Piaggio UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction World Health Organization
More informationClinical Appropriateness Guidelines: Advanced Imaging
Clinical Appropriateness Guidelines: Advanced Imaging Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry Effective Date: September 5, 2017 Proprietary Date of Origin: 05/21/2007
More informationHormone Replacement Therapy (HRT) Benefits & Risks - The Facts
Hormone Replacement Therapy (HRT) Benefits & Risks - The Facts HRT is a prescription only treatment that replaces some of the lost oestrogen and progesterone hormones which occur during menopause. It can
More informationBone Mineral Density in a Cohort of Young Adult Women using Depoprovera and Tenofovir, Kampala, Uganda
Bone Mineral Density in a Cohort of Young Adult Women using Depoprovera and Tenofovir, Kampala, Uganda Flavia Matovu Kiweewa, Noah Kiwanuka, Delia Scholes, Esther Isingel, Mary Glenn Fowler, Clemensia
More information11/25/2012. Chapter 7 Part 2: Bones! Skeletal Organization. The Skull. Skull Bones to Know Cranium
Chapter 7 Part 2: Bones! 5) Distinguish between the axial and appendicular skeletons and name the major parts of each 6) Locate and identify the bones and the major features of the bones that compose the
More informationContractor Number 03201
Local Coverage Article for Bone Mass Measurements Coverage - 2012 CPT Updates (A51577) Contractor Information Contractor Name Noridian Administrative Services, LLC opens in new window Contractor Number
More informationThe Skeletal System. Mosby items and derived items 2010, 2006, 2002, 1997, 1992 by Mosby, Inc., an affiliate of Elsevier Inc.
The Skeletal System Functions of Skeletal System Provides internal framework that supports the body Protects internal organs Helps fight disease by producing white blood cells 2 Functions of Skeletal System
More informationHormonal contraception and HIV risk
Hormonal contraception and HIV risk Jared Baeten, MD, PhD Departments of Global Health, Medicine, and Epidemiology, University of Washington On behalf of the ECHO Consortium HPTN Annual Meeting Washington
More informationPrescribing of anti-osteoporotic therapies following the use of Proton Pump Inhibitors in general practice
Prescribing of anti-osteoporotic therapies following the use of Proton Pump Inhibitors in general practice B. McGowan, K. Bennett, J. Feely Department of Pharmacology & Therapeutics, Trinity Centre for
More informationFRAX, NICE and NOGG. Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield
FRAX, NICE and NOGG Eugene McCloskey Professor of Adult Bone Diseases University of Sheffield Disclosures Research funding and/or honoraria and/or advisory boards for: o ActiveSignal, Amgen, Bayer, Boehringer
More informationLong Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator
Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2014 Publication date 30 September 2014 A National Statistics Publication for Scotland
More informationBad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism
Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed
More informationRisk Ratio and Odds Ratio
Risk Ratio and Odds Ratio Risk and Odds Risk is a probability as calculated from one outcome probability = ALL possible outcomes Odds is opposed to probability, and is calculated from one outcome Odds
More informationBones are made up of bone cells and tissues Hard, dense and smooth outer materials, which are made of calcium, give bones there shape and strength.
1. 2. 3. 4. To protect your body and give it shape. To protect your internal organs. To provide a scaffolding for your muscles, allowing you to move. To store minerals and make blood cells. Bones are made
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationRadiography. 1. Introduction. 2. Documentation of Compliance. 3. Didactic Competency Requirements. 4. Clinical Competency Requirements
PRIMARY CERTIFICATION AND REGISTRATION Radiography 1. Introduction Candidates for certification and registration are required to meet the Professional Education Requirements specified in the ARRT Rules
More informationORILISSA (elagolix) oral tablet
ORILISSA (elagolix) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationContraceptives. Kim Dawson October 2010
Contraceptives Kim Dawson October 2010 Objectives: You will learn about: The about the different methods of birth control. How to use each method of birth control. Emergency contraception What are they?
More informationRESEARCH. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores
Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores Julia Hippisley-Cox, professor of clinical epidemiology and general
More informationContraception: The Pill Needs to Share (or Move Over) Frankly Speaking EP 17
Contraception: The Pill Needs to Share (or Move Over) Frankly Speaking EP 17 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional
More informationReproductive health research at WHO
Reproductive health research at WHO Paul F.A. Van Look, MD PhD Department of Reproductive Health and Research World Health Organization Geneva, 11 March 2004 PVL_GE_StudCourse_MAR04/1 Health is a state
More informationCollagen Crosslinks, Any Method
190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement
More informationHong Qiu ALL RIGHTS RESERVED
2011 Hong Qiu ALL RIGHTS RESERVED ANTI-DIABETIC TREATMENT AND CANCER OCCURRENCE AMONG PATIENTS WITH TYPE II DIABETES MELLITUS By HONG QIU A dissertation submitted to the School of Public Health University
More informationOsteoporosis as a Focus for Practice Improvement
Osteoporosis as a Focus for Practice Improvement Karen E. Hansen, M.D. Assistant Professor of Medicine Rheumatology and Endocrine Sections University of Wisconsin Madison, WI Postmenopausal Osteoporosis
More informationACCIDENT CLAIM DOCTOR S STATEMENT
ACCIDENT CLAIM DOCTOR S STATEMENT For Official Use _ G E L S Name of Life Assured: NRIC/ Passport No.: 1. of Accident: of first consultation for this current condition: (s) of subsequent consultation(s):
More informationOne-day Essentials Contraception. Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire
One-day Essentials Contraception { Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire 80% women access contraception from their GP Therefore it is
More informationYOGA ANATOMY. Part Three - Bones. Yoga Teacher Training Robin Bennett 200 RYT
YOGA ANATOMY Yoga Teacher Training Part Three - Bones 2015 Robin Bennett 200 RYT THE HUMAN SKELETON BONE COMPOSITION A femur head with a cortex of compact bone and medulla of trabecular (spongy) bone OSTEOBLASTS
More informationTaking provera with nexplanon
Taking provera with nexplanon The Borg System is 100 % Taking provera with nexplanon Aug 31, 2015. Side effects for everyone are different, and the amount of time that it takes for your body to get used
More informationSponsor / Company: sanofi-aventis and Proctor & Gamble Drug substance(s): Risedronate (HMR4003)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: sanofi-aventis and
More informationThe Musculoskeletal System
The Musculoskeletal System Introduction The skeletal system and muscular system are often considered together because they are close in terms of structure and function. The two systems are referred to
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationBone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?
Scan for mobile link. Bone Densitometry What is a Bone Density Scan (DXA)? Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology
More informationUnderstanding Osteoporosis
Understanding Osteoporosis Professor Juliet E. Compston Published by Family Doctor Publications Limited in association with the British Medical Association IMPORTANT NOTICE This book is intended not as
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThe Skeletal System. Chapter 7a. Skeletal System Introduction Functions of the skeleton Framework of bones The skeleton through life
The Skeletal System Skeletal System Introduction Functions of the skeleton Framework of bones The skeleton through life Chapter 7a Support Protection Movement Storage areas Minerals Lipids Hemopoiesis
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationMusculoskeletal System
Musculoskeletal System The musculoskeletal system gives the body strength, structure, and capability of movement. Bones are the framework. Ligaments and tendons are the nails Muscles are the way we move
More informationCritique of evidence put forward by Servier suggesting an association between acid-suppressive medication and fracture risk. Dr Myfanwy Lloyd Jones
Critique of evidence put forward by Servier suggesting an association between acid-suppressive medication and fracture risk Dr Myfanwy Lloyd Jones February 2008 Background Proton pump inhibitors (PPIs)
More informationMedical Director Update
Medical Director Update Articles: Bone Density Test Can Predict Fractures Over Twenty-Five Years Community Awareness Bone Density Testing Program: 18 Months Experience More Attention Should Be Paid To
More informationPrescriber Guide for the Letairis REMS Program
LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY (REMS) Prescriber Guide for the Letairis REMS Program Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program (November 2018) Revised:
More informationThrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor
Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor Dr Matthew Fay GP Principal The Willows Medical Practice- Queensbury GPwSI and Co-Founder Westcliffe Cardiology Service
More informationAnatomy. Anatomy deals with the structure of the human body, and includes a precise language on body positions and relationships between body parts.
Anatomy deals with the structure of the human body, and includes a precise language on body positions and relationships between body parts. Proper instruction on safe and efficient exercise technique requires
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationMeta-analysis: analysis:
1 Diabetes and TZDs: Risk Factors for Fracture Ann Schwartz, PhD Dept. of Epidemiology and Biostatistics University of California San Francisco July 2010 Osteoporosis CME Presenter Disclosure Information
More informationBreast Cancer Risk in Patients Using Hormonal Contraception
Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationDEPO-PROVERA/DEPO-PROVERA-SC (medroxyprogesterone acetate) - Product Monograph Page 55 of 61
PART III: CONSUMER INFORMATION DEPO-PROVERA DEPO-PROVERA-SC Medroxyprogesterone acetate Sterile Aqueous Suspension 50 mg/ml, 104 mg/0.65 ml and 150 mg/ml This leaflet is Part III of a three-part "Product
More informationSet Your World in Motion. Skeleton measurement
Set Your World in Motion Skeleton measurement What is skeleton measurement? Use measurement tools, according to the definition of the size of the bones in various parts of the actor s body is measured
More informationPhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More information1 Case Control Studies
Statistics April 11, 2013 Debdeep Pati 1 Case Control Studies 1. Case-control (retrospective) study: Select cases, Select controls, Compare cases and controls 2. Cutaneous melanoma (Autier, 1996). 420
More informationThe Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial
The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial A Multi-Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women using Depot Medroxyprogesterone
More informationRoundtable on Generic RH Commodity Supply Among Developing Countries
Roundtable on Generic RH Commodity Supply Among Developing Countries SOUTH AFRICA REPORT Beijing, China 6-10 November 2006 John-Heyns Ferreira AFRICA SHOWING SOUTH AFRICA SOUTH AFRICA 9 PROVINCES IN SOUTH
More informationConfounding Bias: Stratification
OUTLINE: Confounding- cont. Generalizability Reproducibility Effect modification Confounding Bias: Stratification Example 1: Association between place of residence & Chronic bronchitis Residence Chronic
More informationParathyroid Hormone Analogs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.36 Subject: Parathyroid Hormone Analogs Page: 1 of 6 Last Review Date: September 15, 2017 Parathyroid
More informationChapter 5 The Skeletal System
Chapter 5 The Skeletal System The Skeletal System Parts of the skeletal system Bones (skeleton) Joints Cartilages Ligaments (bone to bone)(tendon=bone to muscle) Divided into two divisions Axial skeleton:
More informationThe skeletal system is the framework for the muscular system to attach to so we can move.
Skeletal System The skeletal system is the framework for the muscular system to attach to so we can move. BONE: A rigid connective tissue Helps to move & support the body Protect the organs (skull, ribs)
More informationMedicine and the Current Correlation Between Fosamax and Fractures
Medicine and the Current Correlation Between Fosamax and Fractures American Association for Justice Fosamax Telseminar June 22, 2011 2:00 3:30 pm EDT By: William B. Curtis Michael S. Wilson Curtis Law
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOmnisense: At Least As Good As DXA
Omnisense: At Least As Good As DXA The following document summarizes a series of clinical studies that have been conducted to compare between different qualities of the Sunlight support the claim that
More informationContraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE
Contraception Choices: An Evidence Based Approach Case Study Approach Susan Hellier PhD, DNP, FNP-BC, CNE Objectives Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)
More information[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationDeclining endocervical rates: does it matter? Dorota Gertig Medical Director, VCCR
Declining endocervical rates: does it matter? Dorota Gertig Medical Director, VCCR Background Outline Current recommendations Australian and international Review key studies Data from AIHW and VCCR Analysis
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationGOLDEN PROTECTOR CLAIM DOCTOR S STATEMENT
GOLDEN PROTECTOR CLAIM DOCTOR S STATEMENT * Please delete where appropriate For Official Use _ G E L S Name of Life Assured: NRIC/ Passport No.: of Birth (dd/mm/yyyy): Gender: M / F * 1. of Accident: of
More informationBones of Thorax (Rib Cage)
Musculoskeletal System (Part A-2) Module 7 -Chapter 10 Overview Muscles Attachments Bones Bone types Surface features of bones Divisions of the skeletal system Joints or Articulations Susie Turner, M.D.
More information